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Kinase inhibitors are attractive drugs/drug candidates for the treatment of cancer. The most recent 
literature has highlighted the importance of multi target kinase inhibitors, although a correct 
balance between specificity and non-specificity is required. In this view, the discovery of multi-
tyrosine kinase inhibitors with subfamily selectivity is a challenging goal. Herein we present the 
synthesis and the preliminary kinase profiling of a set of novel 4-anilinopyrimidines. Among the 
synthesized compounds, the N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives selectively 
targeted some members of class III receptor tyrosine kinase family. Starting from the structure of 
hit compound 19 we synthesized a further compound with an improved affinity toward the class III 
receptor tyrosine kinase members and endowed with a promising antitumor activity both in vitro 
and in vivo in a murine solid tumor model. Molecular modeling simulations were used in order to 
rationalize the behavior of the title compounds.
Protein kinases (PKs) are key enzymes that regulate almost all cell processes. PKs transfer a phosphate 
group from ATP (or GTP) to specific residues (mainly tyrosine, threonine or serine) located in the 
target proteins, thus promoting specific pathways1,2. The human kinome contains 518 different protein 
kinases grouped into eight major families on the basis of structural similarity2,3. The overexpression or 
deregulation of kinases (in particular tyrosine kinases, TKs) are often linked to cancer onset and progres-
sion4. Hence, TKs are among the major classes of biological targets for modern cancer therapy5. The TK 
family contains both receptor (RTK) and cytoplasmic enzymes3. Among the RTKs, of particular interest 
are the ErbB family6 (or class I RKT, comprising the four receptors ErbB1-4) and the platelet-derived 
growth factor family7 (PDGF; or class III RTK). Activating mutations of ErbB1 (also known as epidermal 
growth factor receptor, EGFR) are correlated with onset and progression of different solid cancers8 and 
in particular with lung cancer9. Mutations in class III RTK members (i.e. Fms-like TK-3, FLT3; colony 
stimulating factor-1 receptor, CSF1R; KIT; PDGFRα ; PDGFRβ ) are associated with hyper-proliferative 
pathologies as hematologic neoplasms10,11, lung cancer12 and pancreatic cancer13,14.
The high number of FDA approved drugs in the last 15 years reveals the growing interest in TK inhib-
itors (TKIs)15,16. In most cases, TKIs act as ATP-mimic compounds, although several allosteric inhibitors 
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are under investigations17. Cancer is a multi factorial disease and recent findings have highlighted the 
importance of multi targeting compounds, i.e. compounds able to inhibit, with comparable potencies, 
more than one TK18. However, both selective (e.g. erlotinib and gefitinib) and unselective (e.g. sunitinib 
and dasatinib) kinase inhibitors are useful anticancer drugs. Hence, whether multi-kinase inhibitors have 
significant advantages than single kinase inhibitors is still debated19. Only some specific kinases should 
be targeted by multi-inhibitors to guarantee high efficacy while maintaining an acceptable safety: in 2010 
Morphy used the term “selectively nonselective” TKIs to describe compounds with an ideal profile of 
kinase inhibition20.
Currently, a number of multi kinase inhibitors have been discovered, both by chance and by design19. 
The rational design of “selectively nonselective” TKIs is a challenging and fascinating goal: the ATP 
binding pocket is quite conserved in the entire kinome, and it is particularly conserved inside each PKs 
subfamily. In this view, an achievable and promising aim could be the design/development of subfamily 
selective kinase inhibitors. However, as recently reported, the inhibition of all the members of a single 
subfamily can lead to substantial toxicity21.
The ATP pocket is delimited by the hinge region (containing also the gatekeeper residue), the P-loop, 
the C-helix and the activation loop (containing the highly conserved DFG motif; Fig.  1a). The ATP 
binding pocket is constituted by the adenine pocket, the hydrophilic ribose pocket and two hydrophobic 
regions (Fig.  1b,c). Accordingly, TKIs are commonly constituted by i) a nitrogen containing hetero-
cycle able to form an H-bond with the hinge region; ii) an hydrophobic moiety interacting with the 
hydrophobic region I of the kinase; iii) a spacer between the heterocycle and the hydrophobic moiety 
(Fig. 1d,e)15,22.
Figure 1. Structure of kinases and of designed compounds. (a) Main element in kinase structure. (b) 
Binding of AMP-ANP (PDB ID: 2GS7). (c) Schematic representation of binding of ATP and features of the 
ATP binding pocket. (d) Detail of binding of a kinase inhibitor (erlotinib; PDB ID: 1M17). (e) Schematic 
representation of binding of inhibitor (erlotinib) with respect to the features of the ATP binding pocket. 
Image partially readapted from ref. 22. (f) General structures of designed compounds and their structural 
relationship with 4-anilinoquinazolines. (g) Supposed binding mode of designed compounds in the ATP 
binding pocket.
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A recurring motif in kinase inhibitors is the pyrimidine nucleus. Some symmetric 
4,6-dianilinopyrimidines were reported as selective EGFR inhibitors23. However, the selectivity profile 
was reported only for few compounds23. Similar compounds were also patented by Avila therapeutics 
(WO2009/051822), but few kinases were considered as targets. A number of 4-anilino-6-phenylpyrimidines 
were patented as cyclin-dependent kinase (CDK) inhibitors (see for example WO2008/129080 and 
WO2011/077171). Phosphorous containing pyrimidines as CDK inhibitors were recently published24. 
Examples of FDA approved pyrimidine based TKIs are imatinib25 (Abl/KIT/PDGFRβ inhibitor) and 
dasatinib26 (dual Abl/Src inhibitor). Examples of compounds involved in clinical trials are BAY100039427 
and the fused pyrimidine PHA-84812528 (pan CDK inhibitors). Nevertheless, in most cases the pyrimi-
dine nucleus is not the main “nitrogen containing heterocycle”, since it does not interact with the hinge 
region, as shown by X-ray crystallography29.
Another interesting class of TKIs is constituted by the 4-anilinoquinazolines30. These compounds 
are mainly known as high selective EGFR31, dual EGFR/ErbB232 or dual EGFR/VEGFR233 (vascular 
endothelial growth factor receptor-2). We have recently reported that the m-biphenylamine as aniline 
moiety led to multi kinase inhibitors targeting EGFR, fibroblast growth factor receptor-1 (FGFR1), 
VEGFR2, PDGFRβ , Src and Abl at nanomolar concentrations34,35. Indeed, 4-anilinoquinazolines could 
be considered as fused pyrimidine (i.e. 4-anilinobenzopyrimidine).
On these basis, we planned the synthesis of novel potential TKIs bearing the 4-anilinopyrimidine core 
as the nitrogen containing heterocycle (Fig. 1f). The compounds were further characterized by 5-phenyl, 
6-phenyl or 6-phenylamino moieties designed to interact with the hydrophobic region II of the ATP 
pocket, the ribose pocket or the DFG motif (Fig. 1g). The 4-anilino portion of the compounds was sup-
posed to interact with the hydrophobic pocket I (HP-I) of the kinase, in analogy to 4-anilinoquinazolines. 
The interactions with HP-I have often been used to obtain selectivity in kinase inhibitions36–38. For exam-
ple, very small differences in position or nature of 4-anilinosubstituent in quinazoline compounds led to 
selective EGFR39, VEGFR240 or janus kinase (JAK)41 inhibitors. Hence, we functionalized the 4-anilino 
moiety with substituent differing in the hydrophobicity/hydrophilicity, in the ability to act as H-bond 
donor or acceptor, in the position and in the size. Since our purpose was to determine how the function-
alization of the pyrimidine nucleus at 4 and 5 or at 4 and 6 positions could modulate the kinase selec-
tivity profile, at this stage, we considered only simple commercially available or easily accessible anilines. 
Several papers and patents describing very similar compounds as kinase inhibitors are present in liter-
ature (a selection of representative bibliography is reported in Table S2). The novelty of our work relies 
in the evaluation of a library of simple 4-anilinopyrimidines against a wide panel of kinases and human 
cancer cell lines to discover novel “selective unselective” hit compounds. Indeed, through this approach 
we identified the 6-phenyl-4-anilinopyrimidine derivative 19 as a selective dual KIT/PDGFRβ inhibi-
tor. Compound 19 was further improved, leading to a novel and more potent KIT/PDGFRα /PDGFRβ 
inhibitor (27) endowed with a promising anticancer potential. Molecular modeling studies were used to 
clarify the structure activity relationships emerged by Kd determination. Since both 19 and 27 targeted 
only few specific members of a TK family, they can be considered as novel “selectively nonselective” TKIs.
Results
Compounds synthesis. The structures of synthesized compounds are reported in Fig.  2 (see also 
Table S1).
Compounds 1–7 and 8–12 were obtained starting from 4,6-dichloropyrimidine 28 (Fig. 3a). In case 
of unsymmetrical compounds (1–7), compound 28 was first condensed with a slight excess of aniline 
in i-PrOH in the presence of triethylamine (TEA) and then with the appropriate aniline derivatives 
in i-PrOH, in both cases taking advantage from the Microwave Assisted Organic Synthesis (MAOS). 
Diarylurea derivative 7 was obtained by the reaction of aminoderivative 6 with phenyl isocyanate in 
dichloromethane.
In case of symmetrical compounds (8–12), compound 28 was reacted with a double amount of the 
appropriate aniline derivatives, but in this case, the nucleophilic aromatic substitutions were performed 
in i-PrOH at reflux without the presence of TEA.
Compounds 13–19 were synthesized starting from ethyl benzoylacetate (30; Fig.  3b) which was 
reacted with thiourea in anhydrous alkaline medium obtaining the corresponding thiopyrimidinol 31. 
The thiol function was removed through Ni-Raney reduction. Compound 32 was then activated toward 
nucleophilic substitution by reaction with POCl3/TEA. Finally, the chloropyrimidine 33 was condensed 
with the appropriate aniline derivatives in i-PrOH, under microwave irradiation. Compound 19 was 
obtained from aminoderivative 18 as above described for compound 7.
Compounds 20–26 were synthesized adapting a previously reported synthetic strategy42 (Fig.  3c). 
Thiourea 34 was firstly condensed with N,N-dimethylformamide dimethyl acetal and then treated with 
iodomethane in order to elicit the nucleophilic properties of the sulfur atom. Intermediate 36 was then 
reacted with phenylacetyl chloride in the presence of TEA. In this case we did not remove the sul-
fur function at this stage. In fact, the process worked better first activating compound 37 toward the 
nucleophilic aromatic substitution, then reacting compound 38 with the appropriate anilines and finally 
removing the sulfur function with the Ni-Raney system. Compound 26 was obtained from aminoderiv-
ative 25 as above described for compound 7.
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Among all the synthesized compounds, only two were previously reported: compound 5 was cited as 
synthetic intermediate43, whereas 8 was patented by Zeneca (US5880130). However, the two compounds 
were not previously screened against a panel of kinases. Compound 19 was commercially available in 
the Ambinter screening library. However, as reported in the Ambinter web site, it might be available only 
under re-synthesis with an extended delay, thus we synthesized it by ourselves. Besides, the compound 
was not present in academic accessible databases (e.g. PubChem, Reaxys).
Tyrosine kinases screening. Synthesized compounds were screened against a panel of 48 
kinases selected within the ScanEDGE subset of DiscoverX (http://www.discoverx.com/services/
drug-discovery-development-services/kinase-profiling/kinomescan/scanedge). The ScanEDGE includes 
97 kinases and is an economical approach to assess compounds selectivity throughout the human kinome. 
All the wt-TKs along with some relevant mutants of Abl1 (T315I) and of EGFR (L858R and L858R/
T790M) were chosen. The remaining 18 targets (3 Tyrosine Kinases-Like, TKLs; 15 Serine-Threonine 
Kinases, STKs) were selected among the remaining kinases in the ScanEDGE subset on the basis of 
their well established role in cancer (see Fig. S2 for a graphical representation of the selected kinases 
with reference to the kinome tree. Some references highlighting the role of each kinase in cancer are 
also reported in Table S3).
The compounds were evaluated using the KinomeScan™ platform (http://www.discoverx.com/ser-
vices/drug-discovery-development-services/kinase-profiling/kinomescan), that measures the ability of the 
test compound to disrupt the complex between a high affinity ATP-mimic probe immobilized on a solid 
support and the kinase of interest. The KinomeScan is a very helpful technology for the fast and reliable 
screening of a number of compounds against a wide and customizable panel of kinases. Besides, it is not 
based on the use of hazardous radioactive 32P-ATP and has a very low rate of false positive (< 1%)44. The 
screening platform outputs a “Percent of Control” (POC) value, statistically correlated to the dissociation 
constant (Kd) value (http://www.discoverx.com/tools-resources/leadhunter-study-reports-data-analysis), 
for each pair of kinase/ligand. The POC is calculated as reported in equation (1):
Figure 2. Structures of synthesized compounds. 
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=
−
−
×
( )
POC
test compound signal positive control signal
negative control signal positive control signal
100
1
Where: test compound signal = amount of kinase still binding the probe after treatment with test com-
pound; negative control signal = amount of kinase still binding the probe after treatment with DMSO 
(100% control); positive control signal = amount of kinase still binding the probe after treatment with 
control compound (0% control). Hence, low POC values indicate high affinity.
The compounds were tested at high concentration (10 μ M), in order to highlight not only the main 
target but also the off-targets. The results of the preliminary screening are reported as heat map (Fig. 4; 
see also Table S4 for all the measured values), in which the compounds are grouped on the basis of the 
6 or 5 substituent at the pyrimidine ring.
All the tested compounds were almost inactive against both TKL and STK members. The 
6-phenylamino compounds targeted the ErbB family (comprising the wt-EGFR, ErbB2 and the two 
EGFR mutants L858R and L858R/T790M). Similarly to what previously reported23, these derivatives were 
mainly active against wt-EGFR, although with different potencies. Some 6-phenylamino compounds and 
the three phenylurea derivatives (7, 19 and 26) were active against the members of the class III RTKs 
family.
Structure activity relationship. Overall, 4-anilinopyrimidines targeted mainly the ErbB and the 
class III RTKs subfamilies.
With respect of targeting EGFR, the presence of a 5-phenyl or a 6-phenyl ring was detrimental (com-
pare 1 with 13 and 20; Fig.  5a). Hence, only 6-phenylamino-4-anilinopyrimidines were active against 
Figure 3. Synthesis of compounds 1–26. See Fig. 2 for R specification.
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EGFR. For these compounds, the substitution of the 4-aniline moiety with small meta lipophilic substit-
uents was preferred (e.g. potencies: 1m−Me > 4p−Me; 8m−Me = 1m−Me = 9m−Br > 11p−Cl). Conversely to what 
previously reported for 4-anilinoquinazolines34, a biphenylamino moiety was detrimental (see 2 and 
10). The L858R mutation (that causes an enhancement of the kinase activity without directly modifying 
the ATP site45) did not affect the ligand binding, whereas the T790M gatekeeper mutation dramatically 
impaired the interaction. Despite the high degree of similarity between wt-EGFR and ErbB2, compounds 
were not active against the latter kinase. The presence of small meta hydrophilic function (i.e. 3m−OH) was 
well tolerated, still leading to selective EGFR inhibitors. Interestingly, small para hydrophilic substituents 
(OH, NH2) led to less selective compounds: derivatives 5 and 6 targeted EGFR, some members of the 
class III RTKs and AXL. The lowest selectivity was obtained when the pyrimidine core was functionalized 
at both 4 and 6 position with para-hydroxyaniline moieties: indeed compound 12 targeted a number 
of kinases, comprising also the T790M mutant of EGFR. We are planning further investigation on this 
compound. When the 4-anilino was functionalized with bulky hydrophilic function (i.e. a phenylurea, 
see compound 7), very poor activity against EGFR was observed.
With respect of targeting class III RTKs, as above mentioned, the presence of a para H-bonding 
substituent in the 4-aniline moiety was required (see compounds 5 and 6). When the 4-aniline moiety 
was functionalized with a para-phenylurea substituent, selective class III RTK members inhibition was 
obtained. Indeed, in the case of phenylurea compounds (7, 19 and 26), the functionalization at 5 or 
6 position of the pyrimidine nucleus played a key role in determining the degree of selectivity within 
the subfamily. The inhibition of KIT and PDGFRβ was not affected by pyrimidine substitution at 5 
or 6 position (potencies: 76−Phenylamino = 196−Phenyl = 265−Phenyl). Conversely, the inhibition of PDGFRα 
strongly depended on both the nature and the position of the pyrimidine substituent (potencies: 265−
Phenyl > 196−Phenyl > 76−Phenylamino). The absence of a substituent at the 6 position led to the inhibition of all 
the members of the subfamily (see 265−Phenyl). On the other end, the presence of the 6-phenyl gave the 
highest selectivity (potencies for 196−Phenyl: KIT = PDGFRβ > PDGFRα > CSF1R > FLT3). Finally, the 
introduction of a linker between the phenyl and the pyrimidine nuclei gave an intermediate selectivity 
degree (potencies for 76−Phenylamino: KIT = PDGFRβ = FLT3 > CSF1R > PDGFRα ).
The main structure activity relationships are resumed in Fig. 5b.
Cytotoxicity. Compounds active against at least one kinase among EGFR and class III RTKs were 
evaluated for their cytotoxic properties against two different human cancer cell lines, namely non small 
cells A549 lung cancer cells (sensitive to EGFR inhibitors)46 and pancreatic BxPC3 adenocarcinoma 
(sensitive to both PDGFRβ and EGFR inhibitors)47,48 cells. For comparison purposes, sunitinib (SU), a 
multi-kinase inhibitor49, was evaluated under the same experimental conditions. The results, expressed 
as IC50 values (μ M) calculated from the dose-survival curves obtained after 72 h of drug treatment from 
the MTT test, are reported in Table 1.
The newly synthesized compounds (excluding 8, 9 and 12) showed a cytotoxic potency in the micro-
molar range against both cancer cell lines. In particular, the two phenylurea derivatives 7 and 19 (see 
Fig.  5a for structures) were up to about 6 times more effective than the reference TKI against both 
A549 and BxPC3 cells (see potency relative to SU, calculated as the ratio between IC50 of sunitinib and 
Figure 4. Results of primary screening of compounds against kinases. The heat map displays the results 
of the primary screening in terms of POC values for each pair of kinase/ligand. The lower the POC (white 
to red boxes), the tighter the binding. Compounds are listed according to Fig. 2.
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IC50 of tested compounds in Table 1). Tested against non-tumor cells in rapid proliferation, the human 
embryonic kidney HEK293 cells, 19 elicited selectivity index values (SI = quotient of the IC50 toward non 
cancerous cells divided by the average IC50 for the malignant cells) approximately 1.5-folds higher than 
that calculated with SU, thus attesting a preferential cytotoxicity versus neoplastic cells. On the contrary, 
compound 7 was more cytotoxic against non transformed cells (SI < 1).
Improvement of pharmacodynamic properties of hit compound 19. Based on the kinases 
screening results and on the IC50 and the SI values, we selected derivative 19 as our “hit compound”. As 
mentioned above, the 6-phenyl ring was designed to occupy the hydrophobic pocket II (Fig. 1g), which 
is next to the hydrophilic ribose binding region of the kinases (Fig. 1c). Hence, we tried to improve the 
ability of the hit compound to interact with class III RTK members through the insertion of a small 
hydrophilic moiety, intended to occupy the sugar pocket of the kinases, thus obtaining compound 27 
(Fig. 6; see also Supplementary Information for details on synthetic procedures).
The ability of compounds 19 and 27 to bind the class III RTK members was measured (Table 2; see 
also Figs S3 and S4 for dose/response curves).
As supposed, the further functionalization of the 6-phenyl ring with a polar moiety able to interact 
with the sugar pocket improved the binding affinity toward all the tested kinases. Nevertheless, for both 
compounds the main target remained KIT. The highest affinity improvement was observed for PDGFRα 
(nearly an order of magnitude), whereas the interaction with PDGFRβ was not substantially modified. 
Compound 19 was confirmed as a dual KIT/PDGFRβ inhibitor, while compound 27 should be consid-
ered as a KIT/PDGFRα /PDGFRβ inhibitor.
The cytotoxic profile of 19 and 27 was assessed on a wider panel of human tumor cell lines including 
also examples of breast (MCF-7), cervical (A431), colorectal (HCT-15), and ovarian (2008) cancers as 
Figure 5. Structure activity relationships for 4-anilino compounds. (a) Selectivity profile of some selected 
compounds highlights the features required for selective EGFR, dual EGFR/class III RTKs or selective class 
III RTKs inhibition. (b) Schematic representation of main structure activity relationships with respect to 
4-anilinopyrimidine core.
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well as melanoma (A375), besides lung (A549) and pancreatic (BxPC3) cancer cells. IC50 values, cal-
culated from the dose-survival curves obtained after 72 h of drug treatment from the MTT test, are 
reported in Table 2. Anilinopyrimidines 19 and 27 showed a quite similar pattern of cytotoxicity over the 
cancer cell lines panel. Both compounds were endowed with a cytotoxic potency higher than that of SU, 
eliciting IC50 values in the low micromolar range. Notably, IC50 values measured on pancreatic adenocar-
cinoma BxPC3 cells were in the sub-micromolar range, exceeding by a factor of 6 those detected with the 
reference TKI. When tested against non-cancer HEK293 cells, derivative 27 showed an antiproliferative 
activity even lower than that of the parental compound 19, eliciting an average IC50 value of 10 μ M, thus 
suggesting a preferential activity towards cancerous cells.
Preliminary in vivo evaluation of lead compound 27. Basing on in vitro screening, derivative 27 
emerged as the most interesting compound since it was more effective than 19 against target kinases. 
Besides, it was as cytotoxic as 19 towards cancer cells while showing a more favorable selectivity index. 
On these basis, compound 27 was chosen for in vivo experiments against a syngeneic murine solid 
ID
A549 IC50 
(μM) ± SD
Potency 
relative to 
SU
BxPC3 IC50 
(μM) ± SD
Potency 
relative to 
SU
HEK293 IC50 
(μM) ± SD
Selectivity 
Index
1 8.94 ± 2.18 0.70 6.43 ± 1.78 0.79 – –
2 26.52 ± 3.85 0.23 17.90 ± 2.46 0.28 – –
3 28.25 ± 5.46 0.22 8.19 ± 2.18 0.62 – –
4 14.17 ± 2.75 0.44 23.25 ± 4.29 0.22 – –
5 16.32 ± 4.24 0.38 6.51 ± 1.07 0.78 – –
6 33.98 ± 4.98 0.18 16.13 ± 4.85 0.31 – –
7 5.13 ± 0.94 1.21 4.60 ± 0.85 1.10 3.14 ± 0.57 0.64
8 > 50 < 0.12 > 50 < 0.10 – –
9 > 50 < 0.12 > 50 < 0.10 – –
12 > 50 < 0.12 > 50 < 0.10 – –
19 3.16 ± 1.12 1.97 0.77 ± 0.21 6.56 7.33 ± 1.75 3.84
24 12.08 ± 1.99 0.51 16.43 ± 4.22 0.31 – –
25 26.12 ± 4.55 0.24 27.85 ± 5.28 0.18 – –
26 28.95 ± 5.86 0.21 30.85 ± 4.18 0.16 – –
SU 6.22 ± 1.84 1.00 5.05 ± 1.34 1.00 12.19 ± 2.83 2.14
Table 1.  Cytotoxicity of selected compounds against A549, BxPC3 and HEK293 cell lines.
Figure 6. Synthesis of compound 27. 
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tumor model, the murine Lewis Lung Carcinoma (LLC). The tumor growth inhibition induced by 27 was 
compared with that promoted by cisplatin (CDDP), the most common chemotherapeutic drug used in 
the treatment of lung cancers. Nine days after tumor inoculation, tumor-bearing mice were randomized 
into vehicle control and treatment groups (8 mice per group). Control mice received the vehicle (0.2%v/v 
EtOH and 99.8%v/v of a saline solution), whereas treated groups received daily doses of 27 (7.5 mg · kg−1 
in the vehicle solution composed of 0.2%v/v EtOH and 99.8%v/v of saline solution) or CDDP (1.5 mg · kg−1 
in saline solution). Tumor growth was estimated at day 20 (Fig. 7a). As an indication of the adverse side 
effects, changes in the body weights of tumor-bearing mice were monitored at day 1 and daily from day 
9. The intraperitoneal administration of 27 reduced by 84.7% the tumor mass compared to that of the 
control group (Fig. 7b, Table S5), promoting an in vivo antitumor activity even better than that exerted 
by CDDP which reduced the tumor mass of 71.6%.
Remarkably, even though 27 was administered at higher doses than CDDP, the time course of body 
weight changes indicated a more safety profile for our compound. Indeed, treatment with 27 resulted 
in a moderate body weight loss (< 10%) whereas, as well documented, CDDP provoked elevated body 
weight loss (Fig. 7c).
The molecular basis for class III RTKs subfamily selectivity. To rationalize the selectivity pro-
file showed by compounds 19 and 27, we firstly analyzed some key residues of the ATP-pocket usually 
involved in the binding of TKIs (Fig. 8a).
The class III RTK members mainly differ in:
– the gatekeeper residue (threonine for CSF1R, KIT, PDGFRα and PDGFRβ ; phenylalanine for FLT3). 
Threonine and phenylalanine don’t have similar steric requirements (blocks substitution matrix, BLO-
SUM50, scoreF−T = − 2);
– one amino acid in the DFG region sequence (cysteine for KIT, FLT3, PDGFRα and PDGFRβ ; glycine 
for CSF1R). Cysteine and glycine don’t have similar steric requirements (BLOSUM scoreC−G = − 3);
– the composition of the deeper part of hydrophobic pocket I, accessible only in the inactive kinase 
conformation (usually targeted by type II inhibitors), that was reported to account for the selectivity of 
certain type II kinase inhibitors51. Considering only the amino acids placing the side chains inside the 
binding pocket, the hydrophobic pockets differed only for one amino acid (leucine in KIT; methionine 
in the other kinases). However, leucine and methionine have similar steric requirements (BLOSUM 
scoreM−L = + 2). Remarkably, the sequences xExxxLxxL or xExxxMxxL are quite conserved in the TK 
family (see for example Src, Syk, ZAP70, TRKA, TIE2 and TYK2), thus the composition of the deeper 
part of hydrophobic pocket I could not mainly account for the overall observed selectivity of the 
compounds.
Kinase profiling
Kinase
19 27
Potency 
improvement
Kd (nM) KdRTK/KdKIT Kd (nM) KdRTK/KdKIT Kd19/Kd27
CSF1R 2900 132 1100 110 2.6
KIT 22 1 10 1 2.2
FLT3 4600 209 1300 130 3.5
PDGFRα 960 44 110 11 8.7
PDGFRβ 80 4 70 7 1.1
Cytotoxicity
 
19 27 Sunitinib
IC50 (μ M) ± SD IC50 (μ M) ± SD IC50 (μ M) ± SD
 A549 3.16 ± 1.12 3.11 ± 1.09 12.19 ± 2.83
 BxPC3 0.77 ± 0.21 0.81 ± 0.32 5.05 ± 1.34
 2008 1.98 ± 0.75 1.82 ± 0.73 3.52 ± 1.22
 MCF-7 1.23 ± 0.89 1.55 ± 0.75 2.58 ± 0.85
 A431 2.85 ± 1.03 1.96 ± 0.92 3.89 ± 1.15
 LoVo 7.45 ± 1.53 7.76 ± 1.28 8.18 ± 2.67
 A375 6.41 ± 2.02 5.56 ± 1.39 8.25 ± 2.88
Table 2.  Activities of compounds 19 and 27 on isolated kinases and on cell viability.
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Since both 19 and 27 targeted preferentially KIT, PDGFRα and PDGFRβ , we supposed that the 
simultaneous presence of the threonine as gatekeeper and of the cysteine just before the DFG motif was 
fundamental. Notably, no other TKs (among the tested ones) presented these two features. Hence, we 
concluded that the selectivity observed for some members of the class III RTK was mainly due to the 
presence of the two residues.
Molecular modeling studies were then conducted on both 19 and 27 in order to propose a plausible 
binding mode with the class III RTK members. From among the available crystal structures, we selected 
1T46 for KIT52, 1RJB for FLT353 and 4HW7 for CSF1R54. These structures were chosen on the basis of 
the similarity with 4ASD (VEGFR2 kinase domain in complex with sorafenib55) because of the high 
degree of similarity of sorafenib with our compounds. Remarkably, no structure for PDGFRα and β 
were available in the Protein Data Bank, thus these kinases were no further considered in computational 
simulations. The docking experiments were conducted using the AutoDock software56. The importance 
of the gatekeeper residue suggested the presence of a water molecule mediated H-bond between the N3 
of the pyrimidine and the threonine, as previously reported for the binding of quinazoline derivatives 
and EGFR (see for example the 1M17 PDB structure57). Remarkably, the supposed water molecule was 
not present in the 1T46 and 4HW7 protein structures. As recently reported, AutoDock software was 
Figure 7. In vivo testing of compound 27. Lewis lung carcinoma (LLC) was implanted i.m. (2 · 106 cells 
inoculum) into the right hind leg of 8-week old imbred C57BL mice. Nine days after tumor inoculation 
(palpable tumor), tumor-bearing mice were randomized into vehicle control and treatment groups (8 mice 
per group). Compound 27 was dosed daily at 7.5 mg/kg ip and CDDP was dosed daily at 1.5 mg/kg ip. At 
day 20, animals were sacrificed (i.e., before tumor can cause the animal discomfort), the legs were amputated 
at the proximal end of the femur, and the inhibition of tumor growth was determined according to the 
difference in weight of the tumor-bearing leg and the healthy leg of the animals expressed as % referred 
to the control animals. Control was constituted by vehicle (0.2%v/v EtOH and 99.8%v/v of saline solution). 
CDDP was used as positive reference. Both 27 and CDDP were administered at the highest not toxic doses 
(7.5 and 1.5 mg/kg, respectively), as determined by MTD studies. (a) Average tumor weight (g) after 20 
days of treatment with control or compounds. (b) Percentage of reduction in tumor growth after 20 days of 
treatment with respect to control mice. (c) Body weight changes. The body weight changes of LLC bearing 
C57BL mice treated with vehicle or tested compounds. Each drug was administered daily after 9 days from 
the tumor cell inoculum. Weights were measured at day 1 and daily from day 9. Error bars indicate the 
standard deviation.
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implemented with a specific force field with discrete displaceable waters in order to dock hydrated lig-
ands58. Following this approach, water molecules were added to compounds 19 and 27 and then docked 
in the protein structures (Fig. 8b–e; the full details of the binding mode for 19 and 27 are reported in 
Figures from S5 to S8).
As supposed, a water molecule classified as “strong” by the scoring protocol58 mediated the binding 
of both 19 and 27 with the threonine gatekeeper in KIT and CSF1R kinases, whereas it was displaced 
in FLT3. The lack of the water mediated H-bond in FLT3 was partially replaced by an edge-to-face 
arene-arene interaction between the aniline moiety and the F691, justifying the lower but not negligible 
binding. Beside the H-bonds, an additional edge-to-face arene-arene interaction was observed for the 
4-anilino moiety of both 19 and 27 and the F811 of the DFG domain of KIT (centroids distance: 5.5 Å 
in both cases). The binding mode predicted for 27 in KIT was consistent with the initial hypothesis since 
the hydrophilic moiety interacted with the residues in the ribose pocket (Fig. 8f).
We also investigated the role of cysteine of the DFG domain. The KITC809 (Fig.  8g) showed higher 
surface complementarity than the CSF1RG795 (Fig.  8h) with the urea moiety of the ligand. Moreover, 
the distances between the sulfur atom of C809 and the aniline moiety suggested the formation of a 
Figure 8. Binding mode study on compounds 19 and 27. (a) Sequences of hinge, DGF and hydrophobic 
pocket I regions of the ATP binding pocket for class III RTKs. Black (or red) characters indicate amino acids 
that place the side chain inside the ATP-pocket; grey characters indicate the amino acids that place the side 
chain outside the ATP-pocket. Amino acids that place the side chain inside the ATP-pocket and that differ 
between the five kinases are highlighted in red. The gatekeeper residue number is also reported. (b–f) Results 
of docking simulations: (b) Potential binding mode of 19 (gray stick) with KIT (green sticks); (c) Potential 
binding mode of 27 (blue stick) with KIT (green sticks); (d) Potential binding mode of 19 (yellow sticks) with 
CSF1R (pink sticks); (e) Potential binding mode of 19 (light pink sticks) with FLT3 (cyan sticks); (f) Potential 
binding mode of 27 (blue sticks) with KIT (green sticks and green cartoons), in context with the ATP 
binding site features. The 6-phenyl moiety of compound 27 is placed in the hydrophobic pocket II, whereas 
the hydrophilic function (i.e. the morpholine ring) is placed in the ribose pocket. (g,h) Details of docking 
simulations for compound 19 (yellow sticks) in KIT (blue sticks, panel (g)) and CSF1R (green sticks, panel 
(h)). Compound 19, KITC809 and CSF1RG795 are depicted as transparent surfaces. The gatekeeper residues 
(KITT670 and CSF1RT663) as well as other protein residues are depicted as sticks in order to allow a better 
comprehension of the compound binding modes.
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sulfur-arene interaction59. Furthermore, the higher steric hindrance of C809 constrained the urea moiety 
in a very favorable position to interact with the KITE640 carboxylic function.
Discussion
Tyrosine kinases inhibitors are among the most attractive and promising anti-cancer compounds. Both 
selective and unselective kinase inhibitors have been approved for cancer treatment. For multi-kinase 
inhibitors a correct balance between specificity and non-specificity is required20. In this view, the discov-
ery of compounds with subfamily selectivity is a challenging goal. The development of high-throughput 
screening technology to screen compounds against a number of kinases is having a high impact in the 
discovery of novel hit with interesting selectivity profile60. Due to our interest in discovering novel TKIs, 
we decided to explore the feasibility of obtaining novel multi-target TKIs bearing 4-anilinopyrimidine 
structure. Firstly we synthesized a small focused library of 26 different 4-anilinopyrimidine derivatives: 
the main scaffold was functionalized with different substituent at the 4-anilino moiety and at the 5 and 
6 positions of the pyrimidine nucleus to determine the molecular features required for kinases inhibi-
tion. Then, the library was screened against a panel of 48 different kinases (comprising TKs, TKLs and 
STKs). All the compounds were inactive against STKs and TK-like enzymes. Among TKs, the com-
pounds were able to target mainly EGFR and/or the member of the class III RTKs family (CSF1R, FLT3, 
KIT, PDGFRα and PDGFRβ ). The substitution of the pyrimidine nucleus at 5 or 6 positions was fun-
damental: compounds bearing a 5-phenyl or a 6-phenyl moiety resulted totally inactive against EGFR. 
Conversely, almost all the 6-phenylamino compounds bound both wt-EGFR and L858R-EGFR mutant.
In the case of 6-phenylamino compounds, the 4-anilino moiety could be functionalized with small 
lipophilic substituents (methyl, bromo, chloro) at meta or para positions, with a slight preference for the 
meta position. The functionalization with a small para hydrophilic function (5p−OH, 6p−NH2) extended 
the inhibitory spectrum, leading to EGFR/class III RTK/AXL inhibitors. The introduction of hydroxylic 
functions at both 4-anilino and 6-anilino moieties led to the wider spectrum of activity: compound 12 
was able to target also TRKA and JAK3. Besides, compound 12 retained a low but not negligible activity 
also against the T790M mutant of EGFR. When the 4-aniline was functionalized with a para-phenylurea 
moiety, we obtained a selective class III RTKs inhibitor (7). Compound 7 probably was a type II inhibitor, 
thus requiring an inactive kinase conformation. However, EGFR is known to adopt a Src-like inactive 
conformation61, which substantially differs from the KIT inactive conformation52: the DFG domain of 
inactive EGFR still remains close to the ATP binding pocket, thus limiting the dimension of the hydro-
phobic pocket I and impairing the binding with compound 7. Conversely, inactive KIT adopt a true 
DFG-out conformation with a larger hydrophobic pocket I.
Remarkably, all the compounds bearing the para-phenylurea moiety (7, 19 and 26) were selectively 
active against the class III RTK members. In this case, the substitution at 5 or 6 positions of the pyrim-
idine ring conferred selectivity inside the family: 5-phenyl compound (26) inhibited all the class III 
RTK members with comparable potencies; 6-phenyl compound (19) was a selective dual KIT/PDGFRβ 
inhibitor; 6-phenylamino compound (7) showed an intermediate selectivity degree between 19 and 26.
Compounds active against at least one of the main target kinases (EGFR and/or class III RTKs) were 
screened for their cytotoxic potential against lung and pancreatic cancer cell lines. Many of the studied 
compounds showed a marked in vitro antitumor activity, with IC50 values in the micromolar range. 
However, only 7 and 19 showed lower average IC50 values than the reference multi TKI, sunitinib. In 
addition, when tested against non-tumor cells in rapid proliferation, only compound 19 showed a pref-
erential antiproliferative activity toward neoplastic cells.
Dissociation constant determinations confirmed that compound 19 was a selective dual KIT/PDGFRβ 
inhibitor with nanomolar affinity. The structure of this hit compound was further modified in order to 
improve the pharmacodynamic properties. Hence, compound 27 (designed to interact also with the 
sugar pocket of the target kinases) showed overall lower Kd values against class III RTK members than 
19, resulting a multi KIT/PDGFRα /PDGFRβ inhibitor with nanomolar affinity (Kd against CSF1R and 
FLT3 were higher than 1 μ M).
Tested against a wide panel of cancer cell lines, including examples of breast, ovarian cancers along 
with melanoma, compounds 19 and 27 showed a comparable activity profile and were more effective 
than sunitinib in inhibiting cancer cell proliferation. Remarkably, compound 27 was more selective 
against cancer cells than the hit compound 19. Very preliminary in vivo studies were also conducted 
on compound 27. On LLC murine model of solid tumor, compound 27 promoted a reduction of tumor 
mass higher than CDDP, the most widely used drug in the management of lung neoplasms, coupling 
with a reduced host weight loss. Based on these promising results, we are now planning pharmacokinetic 
studies on compound 27 in order to determine its effective anti-cancer.
Molecular modeling studies were conducted on compounds 19 and 27 to investigate the molecular 
basis for the class III RTKs subfamily selectivity. The threonine as gatekeeper and the presence of a 
cysteine residue in the DFG domain played a key role in determining the selectivity profile. On the 
contrary, the hydrophobic pocket I composition was not fundamental for the selectivity profile. These 
findings suggest that in the design of “selectively unselective” TKIs the gatekeeper and the DFG domain 
compositions must be strongly considered. In particular, the presence of sulfur-arene interactions (for 
CDFG containing kinases) and the role of water mediated hydrogen bonds (for threonine gatekeeper 
containing kinases) may play critical roles. Furthermore, as supposed, docking studies suggested that 
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the 6-phenyl moiety of compound 27 interacted with both the hydrophobic pocket II and with the sugar 
pocket of the kinases.
Overall, our data suggested that the N-phenyl-N’-[4-(6-phenylpyrimidin-4-ylamino)phenyl]urea 
derivatives constitute a promising class of subfamily selective inhibitors of class III RTKs deserving fur-
ther development.
Methods
Computational Methodologies. All the computational studies were carried out on a 4 CPU (Intel 
Core2 Quad CPU Q9550, 2.83 GHz) ACPI × 64 Linux workstation with Ubuntu 12.04 operating system. 
The tridimensional structure of the kinases were downloaded from Protein Data Bank (PDB ID: 4HW7 
for CSF1R in complex with PLX647-OME; 1T46 for KIT in complex with imatinib; 1RJB for FLT3). 
The structures were superimposed using the UCSF Chimera software62 and the ligands, the ions and the 
water molecules were removed. The structure of compounds 19 and 27 were prepared with MarvinSketch 
5.5.0.1 software (www.chemaxon.com/products). The lowest energy conformations and the degree of pro-
tonation at pH 7.4 were determined with OpenBabel software63 using the MMFF94s force field. For all 
the molecules, the appropriate “.pdbqt” files were prepared with the AutoDockTools graphical interface 
of AutoDock 4 software56. Before docking simulations, the “.pdbqt” file of compounds 19 and 27 were 
solvated using the appropriate python script33 (more details are reported in Supplementary Information). 
All the docking studies have been performed with AutoDock4 using a docking box of 52 × 70 × 40 Å 
dimensions (centered on PLX647-OME coordinates) and 0.375 grid spacing. Each docking run con-
sisted of 50 independent searches with a maximum of 2,500,000 energy evaluations based on Lamarkian 
Genetic Algorithm searching engine. For each pair kinase/ligand the lowest energy pose was retained.
Experiments with Cultured Human Cells. All compounds, except derivative 27, were dissolved 
in DMSO just before the experiment, and a calculated amount of drug solution was added to the cell 
growth medium to a final solvent concentration of 0.5%, which had no discernible effect on cell killing. 
Compound 27 was dissolved in a 0.9% NaCl solution just before the experiment.
Sunitinib malate and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were 
obtained from Sigma Chemical Co, St.Louis, USA. Antibody for β -actin and ubiquitin were from Santa 
Cruz Biotechnology (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Cell cultures. Human lung (A549), breast (MCF-7), pancreas (BxPC3), and colon (LoVo) carcinoma 
cell lines along with melanoma (A375) were obtained from American Type Culture Collection (ATCC, 
Rockville, MD). Human non-tumor embryonic kidney HEK293 cells were obtained from European 
Collection of Cell Cultures (ECACC, Salisbury, UK). Human cervical carcinoma A431cells were kindly 
provided by Prof. F. Zunino (Division of Experimental Oncology B, Istituto Nazionale dei Tumori, Milan, 
Italy). Human ovarian cancer 2008 cells were kindly provided by Prof. G. Marverti (Dept. of Biomedical 
Science of Modena University, Italy). Cell lines were maintained in the logarithmic phase at 37 °C in 
a 5% carbon dioxide atmosphere using the following culture media containing 10% fetal calf serum 
(Euroclone, Milan, Italy), antibiotics (50 units ∙ mL−1 penicillin and 50 μ g ∙ mL−1 streptomycin) and 2 mM 
l-glutamine: i) RPMI-1640 medium (Euroclone) for MCF-7, A431, BxPC3 and 2008 cells; ii) F-12 HAM’S 
(Sigma Chemical Co.) for A549 and LoVo cells; iii) D-MEM medium (Euroclone) for HEK293 cells.
Cytotoxicity MTT assay. The growth inhibitory effect towards human cell lines was evaluated by 
means of MTT (tetrazolium salt reduction) assay. Briefly, 3–8 ∙ 103 cells/well, dependent upon the growth 
characteristics of the cell line, were seeded in 96-well microplates in growth medium (100 μ L) and then 
incubated at 37 °C in a 5% carbon dioxide atmosphere. After 24 h, the medium was removed and replaced 
with a fresh one containing the test compound at the appropriate concentration. Triplicate cultures 
were established for each treatment. After 72 h, each well was treated with 10 μ L of a 5 mg ∙ mL-1 MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) saline solution, and after 5 h additional 
incubation, 100 μ L of a sodium dodecylsulfate (SDS) solution in HCl 0.01 M were added. After overnight 
incubation, the inhibition of cell growth induced by the tested complexes was detected by measuring the 
absorbance of each well at 570 nm using a Bio-Rad 680 microplate reader (Bio-Rad, Hercules, CA). Mean 
absorbance for each drug dose was expressed as a percentage of the control untreated well absorbance 
and plotted vs drug concentration. IC50 values represent the drug concentrations that reduced the mean 
absorbance at 570 nm to 50% of those in the untreated control wells.
In vivo anticancer activity toward Lewis Lung Carcinoma (LLC). All studies involving animal 
testing were carried out in accordance with the ethical guidelines for animal research adopted by the 
University of Padua, acknowledging the Italian regulation (D.L.G.S. 116/92) and European Directive 
86/609/EEC as to the animal welfare and protection and the related codes of practice. The experimental 
protocol was approved by the Italian Health Department according to the art. 7 of above mentioned 
D.L.G.S. 116/92. The mice were purchased from Charles River, Italy, housed in steel cages under con-
trolled environmental conditions (constant temperature, humidity, and 12 h dark/light cycle), and ali-
mented with commercial standard feed and tap water ad libitum. The LLC cell line was purchased from 
ECACC, United Kingdom. The LLC cell line was maintained in DMEM (Euroclone) supplemented with 
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10% heat inactivated fetal bovine serum (Euroclone), 10 mM L-glutamine, 100 U mL−1 penicillin, and 
100 μ g · mL−1 streptomycin in a 5% CO2 air incubator at 37 °C. The LLC was implanted intramuscularly 
(i.m.) as a 2 × 106 cell inoculum into the right hind leg of 8 week old male and female C57BL mice 
(24 ± 3 g body weight). After 9 days from tumor implantation (palpable tumor), mice were randomly 
divided into 3 groups (8 animals per group) and subjected to daily i.p. administration of 27 (7.5 mg · kg−1 
dissolved in a vehicle solution composed of 0.2%v/v EtOH and 99.8%v/v of saline solution), cisplatin 
(1.5 mg · kg−1 in saline solution), or the vehicle solution (0.2%v/v EtOH and 99.8%v/v of saline solution). 
At day 20, animals were sacrificed, the legs were amputated at the proximal end of the femur, and the 
inhibition of tumor growth was determined according to the difference in weight of the tumor-bearing 
leg and the healthy leg of the animals expressed as a percentage referring to the control animals. Body 
weight was daily measured and was taken as a parameter for systemic toxicity. All reported values are the 
means ± SD of no less than three measurements. Multiple comparisons were made by the Tukey− Kramer 
test (**p < 0.01; *or °p < 0.05).
Statistical analysis. All the values are the means ± S.D. of not less than three measurements. 
Multiple comparisons were made by ANOVA followed by Tukey–Kramer multiple comparison test, using 
GraphPad Software.
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